• Explore /
  • Poster
  • / Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.

Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.

Abstract Poster

Authors

null

Jonathan L. Kaufman

Winship Cancer Institute of Emory University, Atlanta, GA

Jonathan L. Kaufman , Rachid C. Baz , Simon J. Harrison , Hang Quach , Shir-Jing Ho , Annette J. Vangsted , Philippe Moreau , Simon DJ Gibbs , Ahmed H. Salem , Sheryl Coppola , Jeremy A. Ross , Abdullah A. Masud , Sally Westrup , Jenny Vue , Paulo Cesar Maciag , Orlando Bueno , Nizar J. Bahlis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03314181

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8511)

DOI

10.1200/JCO.2020.38.15_suppl.8511

Abstract #

8511

Poster Bd #

411

Abstract Disclosures

Similar Posters

First Author: Shaji Kumar

First Author: Torben Plesner

First Author: Michael A. Thompson

First Author: Orlando Bueno